In a phase 3 study, Crovalimab was found to be efficacious and well tolerated in people with paroxys...
Read moreJapan’s largest drugmaker Takeda says it aims to seek marketing authorisation for its TAK-755 enzy...
Read moreThe company found themselves facing competitive tenders for the first time in this disease space - t...
Read moreWe summarise the ISPOR Europe 2022 conference including plenary sessions on HTA, patient-centered re...
Read moreWe summarise four handpicked articles from pharmaceutical, pricing and market access that are worth ...
Read moreDigitisation is thought to contribute significant improvements in knowledge generation in drug devel...
Read moreWe compare the rates of positive reimbursement decisions in England and EU4 for orphan drugs approve...
Read moreAmylyx has set the annual price of the ALS drug to $158,000, whereas ICER have suggested the drug sh...
Read moreThis updated bill contains some similar measures to those proposed in March as well as some addition...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read more